|Bid||0.00 x 1100|
|Ask||0.00 x 1400|
|Day's range||26.89 - 27.13|
|52-week range||15.92 - 28.17|
|Beta (5Y monthly)||1.52|
|PE ratio (TTM)||N/A|
|Earnings date||02 Nov 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||28.25|
Intersect ENT (XENT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Amid industry-wide concerns of deferral of elective procedures, Intersect ENT's (XENT) plans to consolidate with an industry behemoth like Medtronic seems a strategically aligned survival plan.
An increase in Intersect ENT's (XENT) operating costs puts pressure on its Q3 bottom line.